# Using GM-CSF as a Host Directed Therapeutic Against COVID-19

> **NCT04400929** · PHASE2 · COMPLETED · sponsor: **Singapore General Hospital** · enrollment: 2 (actual)

## Conditions studied

- COVID
- Sars-CoV2
- ARDS, Human

## Interventions

- **DRUG:** Sargramostim
- **OTHER:** Normal Saline 0.9%

## Key facts

- **NCT ID:** NCT04400929
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-02
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-02-04
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400929, "Using GM-CSF as a Host Directed Therapeutic Against COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04400929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*